Search results for "hepatitis C"

showing 10 items of 820 documents

Interleukin 12 enhances deficient HCV-antigen-induced Th1-type immune response of peripheral blood mononuclear cells

1998

The aim of this study was to examine the possible immunomodulating effects of rhIL-12 on the immune response induced by different hepatitis C virus (HCV) antigens. Freshly isolated peripheral blood mononuclear cells (PBMC) of 33 patients with chronic HCV infection were stimulated with optimal concentrations of antigens from the NS3, NS4, NS5, and core region of HCV in the absence or presence of interleukin12 (IL-12). Stimulation by α-CD3 + α-CD28, lipopolysaccharide (LPS), and pokeweed mitogen (PWM) were used as controls. Proliferation and cytokine production were determined by 3H-thymidine uptake and enzyme-linked immunosorbent assay (ELISA) after 72 hr. After stimulation with antigen or a…

medicine.medical_treatmentHepatitis C virusPokeweed mitogenBiologymedicine.disease_causeVirologyPeripheral blood mononuclear cellInfectious DiseasesImmune systemCytokineAntigenVirologyImmunologyInterleukin 12medicineTumor necrosis factor alphaJournal of Medical Virology
researchProduct

Etiological factors of chronic hepatitis in Italy: a 2014 national survey.

2017

Background The last Italian prevalence survey on chronic hepatitis (CH) conducted in 2001 showed that the hepatitis C virus (HCV) was the main agent associated with CH. Aim The aim of this study was to evaluate epidemiological changes in CH occurring after 13 years. Patients and methods Enrollment of 1392 CH consecutive patients referred to 16 Italian liver units in 2014 scattered all over the country (four in the North, four in the Center, four in the South, and four in the Islands) was performed. Results The mean age of the patients was 58.3 years, with a sex ratio (male/female) of 1.5. HCV infection (also with other etiologies) continues to be the most prevalent etiology (58.1%). However…

nonalcoholic fatty liver diseaseAdultMalemedicine.medical_specialtyPediatricsTime FactorsTime FactorAdolescentHepatitis C virusmedicine.disease_causemetabolic syndrome03 medical and health sciencesYoung Adult0302 clinical medicinechronic hepatitiRisk FactorsEpidemiologyNonalcoholic fatty liver diseasemedicinePrevalenceHumansAgedHepatitis ChronicHepatitisAged 80 and overHepatologybusiness.industryRisk FactorGastroenterologyEntecavirHepatitis CHealth SurveyHepatitis BHepatitis C ChronicMiddle Agedmedicine.diseaseHealth SurveysItaly030220 oncology & carcinogenesisEtiology030211 gastroenterology & hepatologyFemalehepatitis C virus infectionbusinessHumanmedicine.drugEuropean journal of gastroenterologyhepatology
researchProduct

Treating chronic hepatitis C in daily practice with PEG-IFN alfa2B and ribavirin. An Italian multicentre study

2004

peginterferon-alpha2bribavirinhepatitis C
researchProduct

Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis.

2009

BACKGROUND/AIMS: Efficacy of retreatment with pegylated interferon (PEG-IFN) plus ribavirin of non-responders to standard or pegylated IFN plus ribavirin has been assessed in various studies, but sustained virologic response (SVR) rates are variable and factors influencing efficacy and tolerability still remain incompletely defined. We aimed to focus on SVR rates and to identify factors influencing them in this meta-analysis. METHODS: MEDLINE as well as a manual search were used. Studies were included if they were controlled or uncontrolled trials, if they had been published as full-length papers and if they included non-responders to standard or pegylated IFN and ribavirin therapy. Fourtee…

pegylated interferon ribavirin non-responders hepatitis C
researchProduct

Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experi…

2022

HCV elimination; Mental health disorders; Sofosbuvir/velpatasvir Eliminación del VHC; Trastornos de salud mental; Sofosbuvir/velpatasvir Eliminació del VHC; Trastorns de salut mental; Sofosbuvir/velpatasvir Hepatitis C virus (HCV) is prevalent in people with mental health disorders, a priority population to diagnose and cure in order to achieve HCV elimination. This integrated analysis pooled data from 20 cohorts in seven countries to evaluate the real-world effectiveness of the pangenotypic direct-acting antiviral (DAA) sofosbuvir/velpatasvir (SOF/VEL) in people with mental health disorders. HCV-infected patients diagnosed with mental health disorders who were treated with SOF/VEL for 12 w…

real-worldGenotype:Mental Disorders [PSYCHIATRY AND PSYCHOLOGY]:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]Hepacivirus:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Antiviral AgentsMental health disordersVirologyMedicaments antivírics - Ús terapèuticHumans:Other subheadings::/therapeutic use [Other subheadings]sofosbuvir/velpatasvir:trastornos mentales [PSIQUIATRÍA Y PSICOLOGÍA]:Otros calificadores::/uso terapéutico [Otros calificadores]Mental Disorders:virosis::hepatitis viral humana::hepatitis C [ENFERMEDADES]:Virus Diseases::Hepatitis Viral Human::Hepatitis C [DISEASES]HCV elimination; HCV; mental health disorders; real-world; sofosbuvir/velpatasvirHepatitis C:Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [CHEMICALS AND DRUGS]Infectious DiseasesReal-worldSofosbuvir/velpatasvirHCV elimination:acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos [COMPUESTOS QUÍMICOS Y DROGAS]HCVmental health disordersSofosbuvirMalalties mentalsHepatitis C - TractamentViruses
researchProduct

New developments in the management of hepatitis C virus infection: focus on boceprevir

2012

Chronic hepatitis C virus infection is an important public health problem, and the standard treatment (combination of pegylated interferon-α and ribavirin) has an effectiveness rate of only 40%-50%. Novel virus-specific drugs have recently been designed, and multiple compounds are under development. The approval for the clinical use of direct-acting antivirals in 2011 (boceprevir [BOC] and telaprevir, viral NS3 protease inhibitors) has increased recovery rates by up to 70%. Therefore, a highly effective treatment has been envisioned for the first time. This paper focuses on BOC and the implementation of new BOC-based treatment regimes.

viral resistanceNS3business.industryvirusesRibavirinHepatitis C virusStandard treatmentprotease inhibitorsReviewmedicine.disease_causeVirologyVirusTelaprevirchemistry.chemical_compoundchemistryBoceprevirHCVantiviral therapyMedicineEffective treatmentbusinessmedicine.drugBiologics: Targets and Therapy
researchProduct

Single-chain antibodies against a plant viral RNA-dependent RNA polymerase confer virus resistance.

2004

Crop loss due to viral diseases is still a major problem for agriculture today. We present a strategy to achieve virus resistance based on the expression of single-chain Fv fragments (scFvs) against a conserved domain in a plant viral RNA-dependent RNA polymerase (RdRp), a key enzyme in virus replication. The selected scFvs inhibited complementary RNA synthesis of different plant virus RdRps in vitro and virus replication in planta. Moreover, the scFvs also bound to the RdRp of the distantly related hepatitis C virus. T(1) and T(2) progeny of transgenic lines of Nicotiana benthamiana expressing different scFvs either in the cytosol or in the endoplasmic reticulum showed varying degrees of r…

virusesHepatitis C virusAmino Acid MotifsBiomedical EngineeringNicotiana benthamianaBioengineeringmedicine.disease_causeAntibodies ViralVirus ReplicationApplied Microbiology and BiotechnologyVirusPlant VirusesTombusviruschemistry.chemical_compoundRNA polymerasePlant virusTobaccomedicinePlant DiseasesGeneticsbiologyfungifood and beveragesbiology.organism_classificationPlants Genetically ModifiedRNA-Dependent RNA PolymeraseVirologyTombusviridaechemistryViral replicationMolecular MedicineSingle-Chain AntibodiesBiotechnologyNature biotechnology
researchProduct

Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus.

2000

Hepatitis C virus (HCV), the major causative agent of chronic and sporadic non-A, non-B hepatitis worldwide, is a distinct member of the Flaviviridae virus family. These viruses have in common a plus-strand RNA genome that is replicated in the cytoplasm of the infected cell via minus-strand RNA intermediates. Owing to the lack of reliable cell culture systems and convenient animal models for HCV, the mechanisms governing RNA replication are not known. As a first step towards the development of appropriate in vitro systems, we expressed the NS5B RNA-dependent RNA polymerase (RdRp) in insect cells, purified the protein to near homogeneity and studied its biochemical properties. It is a primer…

virusesHepatitis C virusGenetic VectorsRNA-dependent RNA polymeraseHepacivirusViral Nonstructural Proteinsmedicine.disease_causeCell LineSubstrate Specificitychemistry.chemical_compoundTranscription (biology)Sequence Analysis ProteinVirologyRNA polymeraseRibavirinmedicineHumansNS5BPolymeraseHepatologybiologyRNANucleosidesDNA-Directed RNA PolymerasesRNA-Dependent RNA PolymeraseVirologyRecombinant ProteinsNS2-3 proteaseInfectious DiseaseschemistryMutationbiology.proteinRNABaculoviridaeJournal of viral hepatitis
researchProduct

Modulation of Hepatitis C Virus NS5A Hyperphosphorylation by Nonstructural Proteins NS3, NS4A, and NS4B

1999

NS5A of the hepatitis C virus (HCV) is a highly phosphorylated protein involved in resistance against interferon and required most likely for replication of the viral genome. Phosphorylation of this protein is mediated by a cellular kinase(s) generating multiple proteins with different electrophoretic mobilities. In the case of the genotype 1b isolate HCV-J, in addition to the basal phosphorylated NS5A (designated pp56), a hyperphosphorylated form (pp58) was found on coexpression of NS4A (T. Kaneko, Y. Tanji, S. Satoh, M. Hijikata, S. Asabe, K. Kimura, and K. Shimotohno, Biochem. Biophys. Res. Commun. 205:320‐326, 1994). Using a comparative analysis of two full-length genomes of genotype 1b…

virusesHepatitis C virusHepacivirusMolecular Sequence DataImmunologyGene ExpressionReplicationHyperphosphorylationGenome ViralHepacivirusViral Nonstructural Proteinsmedicine.disease_causeMicrobiologyCell LineInterferonCricetinaeVirologymedicineAnimalsHumansPhosphorylationNS5ANS3Base SequencebiologyPestivirusvirus diseasesRNAbiochemical phenomena metabolism and nutritionbiology.organism_classificationVirologyMolecular biologydigestive system diseasesAmino Acid SubstitutionInsect ScienceDNA Viralmedicine.drugJournal of Virology
researchProduct

Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymerase.

2001

The hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp), represented by nonstructural protein 5B (NS5B), has recently emerged as a promising target for antiviral intervention. Here, we describe the isolation, functional characterization, and molecular cloning of a monoclonal antibody (mAb) inhibiting the HCV RdRp. This mAb, designated 5B-12B7, binds with high affinity to a conformational epitope in the palm subdomain of the HCV RdRp and recognizes native NS5B expressed in the context of the entire HCV polyprotein or subgenomic replicons. Complete inhibition of RdRp activity in vitro was observed at equimolar concentrations of NS5B and mAb 5B-12B7, whereas RdRp activities of classica…

virusesHepatitis C virusMolecular Sequence DataBiologyViral Nonstructural Proteinsmedicine.disease_causeBiochemistryAntiviral AgentsViruschemistry.chemical_compoundMiceRNA polymerasemedicineAnimalsAmino Acid SequenceMolecular BiologyNS5BImmunoglobulin FragmentsPolymeraseSubgenomic mRNAMice Inbred BALB CBase Sequencevirus diseasesRNAAntibodies MonoclonalCell BiologyVirologyMolecular biologydigestive system diseasesEpitope mappingchemistrybiology.proteinFemaleEpitope MappingThe Journal of biological chemistry
researchProduct